JP2024530952A5 - - Google Patents
Info
- Publication number
- JP2024530952A5 JP2024530952A5 JP2024508322A JP2024508322A JP2024530952A5 JP 2024530952 A5 JP2024530952 A5 JP 2024530952A5 JP 2024508322 A JP2024508322 A JP 2024508322A JP 2024508322 A JP2024508322 A JP 2024508322A JP 2024530952 A5 JP2024530952 A5 JP 2024530952A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- independently
- heterocycloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021111797 | 2021-08-10 | ||
| CNPCT/CN2021/111797 | 2021-08-10 | ||
| CN2021125725 | 2021-10-22 | ||
| CNPCT/CN2021/125725 | 2021-10-22 | ||
| CNPCT/CN2021/132409 | 2021-11-23 | ||
| CN2021132409 | 2021-11-23 | ||
| CNPCT/CN2022/073977 | 2022-01-26 | ||
| CN2022073977 | 2022-01-26 | ||
| CN2022097840 | 2022-06-09 | ||
| CNPCT/CN2022/097840 | 2022-06-09 | ||
| PCT/CN2022/111050 WO2023016434A1 (en) | 2021-08-10 | 2022-08-09 | Compounds targeting mutant of p53 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024530952A JP2024530952A (ja) | 2024-08-27 |
| JP2024530952A5 true JP2024530952A5 (enExample) | 2025-06-24 |
| JP7897926B2 JP7897926B2 (ja) | 2026-07-30 |
Family
ID=85199878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508322A Active JP7897926B2 (ja) | 2021-08-10 | 2022-08-09 | ｐ５３変異体を標的とする化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240400591A1 (enExample) |
| EP (1) | EP4384510A4 (enExample) |
| JP (1) | JP7897926B2 (enExample) |
| KR (1) | KR20240062147A (enExample) |
| CN (1) | CN117813295A (enExample) |
| AR (1) | AR126747A1 (enExample) |
| AU (1) | AU2022325357A1 (enExample) |
| CA (1) | CA3228559A1 (enExample) |
| CL (1) | CL2024000406A1 (enExample) |
| CO (1) | CO2024001421A2 (enExample) |
| IL (1) | IL310653A (enExample) |
| MX (1) | MX2024001870A (enExample) |
| TW (1) | TW202322796A (enExample) |
| UY (1) | UY39890A (enExample) |
| WO (1) | WO2023016434A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| WO2023147419A2 (en) | 2022-01-27 | 2023-08-03 | Pmv Pharmaceuticals, Inc. | Deuterated compounds for restoring mutant p53 function |
| WO2024041503A1 (en) * | 2022-08-22 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
| CN120265637A (zh) * | 2022-12-08 | 2025-07-04 | 北京加科思新药研发有限公司 | 靶向p53突变体的化合物 |
| WO2024238404A2 (en) * | 2023-05-12 | 2024-11-21 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| JP2026522611A (ja) * | 2023-06-19 | 2026-07-08 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｔｐ５３－ｙ２２０ｃ変異型白血病およびｔｐ５３野生型白血病を処置するための併用療法の方法 |
| WO2025031471A1 (zh) * | 2023-08-09 | 2025-02-13 | 德睿智药(苏州)新药研发有限公司 | 用于调节p53功能的新型杂环类化合物 |
| WO2025055856A1 (zh) * | 2023-09-11 | 2025-03-20 | 长春金赛药业有限责任公司 | p53-Y220C选择性小分子重激活剂化合物、药物组合物及其用途 |
| TW202523285A (zh) * | 2023-10-16 | 2025-06-16 | 大陸商北京加科思新藥研發有限公司 | 靶向ｐ５３突變體的化合物的晶型及其用途 |
| WO2025085725A1 (en) * | 2023-10-20 | 2025-04-24 | Scorpion Therapeutics, Inc. | Methods for treating a p53-associated cancer |
| AU2024295989B2 (en) * | 2023-10-20 | 2026-08-13 | Nutshell Therapeutics (Shanghai) Co., Ltd. | N-sulfonamide nitrogen-containing fused heterocyclic compound, and application thereof |
| WO2025151449A1 (en) * | 2024-01-08 | 2025-07-17 | Photys Therapeutics, Inc. | Bifunctional p53-binding compounds and uses thereof |
| TW202604504A (zh) * | 2024-05-11 | 2026-02-01 | 大陸商上海齊魯製藥研究中心有限公司 | 含氮並環化合物、含其的藥物組合物及其應用 |
| WO2026025042A1 (en) | 2024-07-26 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | P53 targeting compounds and uses thereof |
| WO2026161455A1 (en) * | 2025-01-22 | 2026-07-30 | Antares Therapeutics, Inc. | Methods for treating p53-associated cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053446A1 (en) * | 2001-12-19 | 2003-07-03 | Smithkline Beecham Corporation | Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| EP1587781A1 (en) * | 2002-11-05 | 2005-10-26 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| AR056200A1 (es) * | 2005-09-27 | 2007-09-26 | Wyeth Corp | Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa |
| AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| EP3145512B1 (en) * | 2014-05-19 | 2019-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| MX383904B (es) * | 2016-02-19 | 2025-03-14 | Pmv Pharmaceuticals Inc | Métodos y composiciones para restablecer la función de p53 mutante. |
| CN109836434B (zh) * | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | 噻吩并环类化合物及其合成方法和应用 |
| US11814373B2 (en) * | 2019-09-23 | 2023-11-14 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| CA3183081A1 (en) * | 2020-06-24 | 2021-12-30 | Arnold Levine | Combination therapy for treatment of cancer |
| WO2021262483A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
| CN116249689A (zh) * | 2020-06-24 | 2023-06-09 | 皮姆维制药公司 | 用于再激活突变p53的化合物的伴随诊断工具 |
-
2022
- 2022-08-09 UY UY0001039890A patent/UY39890A/es unknown
- 2022-08-09 CA CA3228559A patent/CA3228559A1/en active Pending
- 2022-08-09 WO PCT/CN2022/111050 patent/WO2023016434A1/en not_active Ceased
- 2022-08-09 JP JP2024508322A patent/JP7897926B2/ja active Active
- 2022-08-09 US US18/682,463 patent/US20240400591A1/en active Pending
- 2022-08-09 EP EP22855415.0A patent/EP4384510A4/en active Pending
- 2022-08-09 IL IL310653A patent/IL310653A/en unknown
- 2022-08-09 TW TW111129901A patent/TW202322796A/zh unknown
- 2022-08-09 MX MX2024001870A patent/MX2024001870A/es unknown
- 2022-08-09 KR KR1020247007358A patent/KR20240062147A/ko active Pending
- 2022-08-09 AU AU2022325357A patent/AU2022325357A1/en active Pending
- 2022-08-09 AR ARP220102141A patent/AR126747A1/es not_active Application Discontinuation
- 2022-08-09 CN CN202280055974.2A patent/CN117813295A/zh active Pending
-
2024
- 2024-02-09 CL CL2024000406A patent/CL2024000406A1/es unknown
- 2024-02-09 CO CONC2024/0001421A patent/CO2024001421A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534610A5 (enExample) | ||
| JP2021514001A5 (enExample) | ||
| JP2023540228A5 (enExample) | ||
| RU2498983C2 (ru) | Соединения фениламинопиримидина и их применения | |
| RU2214997C2 (ru) | Производные адамантана, способ их получения, фармацевтическая композиция и способ получения фармацевтической композиции | |
| JP2024529070A5 (enExample) | ||
| JP2013505903A5 (enExample) | ||
| JP2023500611A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| JP2021529812A5 (enExample) | ||
| JP2020503297A5 (enExample) | ||
| JP2017526636A5 (enExample) | ||
| JP2009544602A5 (enExample) | ||
| JP2024517498A5 (enExample) | ||
| JP2005508349A5 (enExample) | ||
| JP2024529527A5 (enExample) | ||
| JP2020511452A5 (enExample) | ||
| JP2021519776A5 (enExample) | ||
| JP2021535174A5 (enExample) | ||
| JP2007502295A5 (enExample) | ||
| JP2018525430A5 (enExample) | ||
| JP2024502175A5 (enExample) | ||
| RU2018126959A (ru) | Кфтр регуляторы и способы их применения | |
| JP2017534569A5 (enExample) | ||
| JP2024507139A5 (enExample) |